Radiopaque intraluminal stents comprising cobalt-based alloys with primarily single-phase supersaturated tungsten content
Embodiments are directed to radiopaque implantable structures (e.g., stents) formed of cobalt-based alloys that comprise cobalt, chromium, tungsten, and nickel. Tungsten is present above its solubility limit (about 15%), but is still only present as a super-saturated, primarily single-phase material exhibiting an FCC microcrystalline structure.
1. A radiopaque stent, comprising:
a cylindrical main body comprising a cobalt-chromium alloy including cobalt and chromium, the cobalt-chromium alloy including tungsten as a radiopacity increasing element, the tungsten comprising about 20% to about 35% by weight of the cobalt-chromium alloy, the tungsten content being super-saturated, above the solubility limit of tungsten in the cobalt-chromium alloy;
wherein the cobalt-chromium alloy further comprises nickel, the nickel being present in a concentration of 5% to about 15% by weight; and
wherein the cobalt-chromium alloy exhibits a primarily single-phase FCC solid solution, wherein a second phase of the tungsten is present and makes up no more than 10% volume fraction in the cobalt-chromium alloy, the second phase having an average particle size of less than 5 μm, even with the super-saturated tungsten content.
2. The radiopaque stent of claim 1 , wherein the cobalt-chromium alloy comprises cobalt in an amount from about 30% to about 50% by weight of the cobalt-chromium alloy.
3. The radiopaque stent of claim 1 , wherein the cobalt-chromium alloy comprises chromium in an amount of about 20% by weight of the cobalt-chromium alloy.
4. The radiopaque stent of claim 1 , wherein the cobalt-chromium alloy comprises nickel in an amount of about 10% by weight of the cobalt-chromium alloy.
5. The radiopaque stent of claim 1 , wherein the cobalt-chromium alloy is entirely free of molybdenum.
6. The radiopaque stent of claim 1 , wherein the cobalt-chromium alloy comprises no more than 1% of silicon, phosphorus, and/or sulfur by weight.
7. The radiopaque stent of claim 1 , wherein the cobalt-chromium alloy further comprises manganese in a concentration of up to 5% by weight of the cobalt-chromium alloy.
8. The radiopaque stent of claim 1 , wherein the cobalt-chromium alloy further comprises iron in a concentration of up to 5% by weight of the cobalt-chromium alloy.
9. The radiopaque stent of claim 1 , wherein the cobalt-chromium alloy further comprises both manganese and iron in a concentration of about 1.5% each, by weight.
10. The radiopaque stent of claim 1 , wherein cobalt comprises from about 66 to 68% by weight of the cobalt-chromium alloy.
11. The radiopaque stent of claim 1 , wherein a weight percent ratio of tungsten to cobalt is at least 0.4.
12. The radiopaque stent of claim 1 , wherein a ratio of tungsten to cobalt is from 0.4 to 1.2.
13. The radiopaque stent of claim 1 , wherein a ratio of tungsten to cobalt is from 0.40 to 0.45.
14. The radiopaque stent of claim 1 , wherein a ratio of tungsten to cobalt is from 0.57 to 0.63.
15. The radiopaque stent of claim 1 , wherein a ratio of tungsten to cobalt is from 1.07 to 1.13.
16. The radiopaque stent of claim 1 , wherein the cobalt-chromium alloy is substantially free of carbon.
17. A radiopaque stent, comprising:
a cylindrical main body formed from a single homogenous cobalt-chromium alloy including cobalt, chromium, nickel, and tungsten, the cobalt-chromium alloy not including any other alloying elements in amounts greater than 3% by weight;
the cobalt-chromium alloy including tungsten as a radiopacity increasing element, the tungsten comprising about 20% to about 35% by weight of the cobalt-chromium alloy, the tungsten content being super-saturated, above the solubility limit of tungsten in the cobalt-chromium alloy at ambient temperature;
wherein the cobalt-chromium alloy comprises about 10% by weight nickel; and
wherein the cobalt-chromium alloy exhibits a primarily single-phase FCC solid solution structure, a second phase of the tungsten is present in the cobalt-chromium alloy having a maximum particle size of less than 15 μm, even with the super-saturated tungsten content.
18. The radiopaque stent of claim 17 , wherein the cobalt-chromium alloy is entirely free of molybdenum.
19. The radiopaque stent of claim 17 , wherein the cobalt-chromium alloy is substantially free of carbon.
20. The radiopaque stent of claim 17 , wherein the cobalt-chromium alloy is entirely free of carbon.
21. A radiopaque stent, comprising:
a cylindrical main body comprising a cobalt-chromium alloy including cobalt and chromium, the cobalt-chromium alloy including tungsten as a radiopacity increasing element, the tungsten comprising about 20% to about 35% by weight of the cobalt-chromium alloy, the tungsten content being super-saturated, above the solubility limit of tungsten in the cobalt-chromium alloy;
wherein the cobalt-chromium alloy further comprises nickel, the nickel being present in a concentration of 5% to about 15% by weight;
wherein the cobalt-chromium alloy exhibits a primarily single-phase FCC solid solution, wherein no more than 10% volume fraction of a second phase of the tungsten is present in the cobalt-chromium alloy, the second phase having an average particle size of less than 5 μm, even with the super-saturated tungsten content; and
at least one of (i) or (ii):
(i) wherein a ratio of tungsten to cobalt is from 1.07 to 1.13;
(ii) wherein the cobalt-chromium alloy further comprises both manganese and iron in a concentration of about 1.5% each, by weight.
22. The radiopaque stent of claim 1 , wherein the tungsten comprises 25% to about 30% by weight of the cobalt-chromium alloy.